KEYNOTE-671
KEYNOTE-671: Pembrolizumab or Placebo + Platinum-Based Neoadjuvant Chemotherapy Followed by Resection and Adjuvant Pembrolizumab or Placebo in Early-Stage NSCLC

Released: June 08, 2023

Activity

Progress
1
Course Completed